Affordable Access

Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated receptor gamma agonist triggers cell survival pathways.

Authors
  • Ptak-Belowska, A
  • Pawlik, M W
  • Krzysiek-Maczka, G
  • Brzozowski, T
  • Pawlik, W W
Type
Published Article
Journal
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
Publication Date
Dec 01, 2007
Volume
58
Issue
4
Pages
793–801
Identifiers
PMID: 18195488
Source
Medline
License
Unknown

Abstract

Peroxisome proliferator-activated receptor gamma (PPAR gamma) are members of the largest nuclear hormone receptor family of transcription factors (1). PPAR gamma (PPARgamma) plays an important role in adipogenesis, control of sensitivity to insulin, inflammation and atherosclerosis but recent studies also suggest that PPARgamma is involved in cell cycle withdrawal. PPARgamma can promote cell differentiation, exert an antiproliferative action and inhibit angiogenesis (2, 3). However, there are studies showing that activation of PPARgamma promotes the development of colon cancer (4). These data are in sharp contrast with studies that attribute anticancer effects to PPARgamma in gastrointestinal malignancies. Probably, the action of PPARgamma on cell cycle and proliferation depends on the cell type and presence of other stimuli that predispose cells to cancer development. Amidated and non-amidated gastrins may play an important role in the proliferation and carcinogenesis of GI cancers. It is known that gastrin peptides activate phosphorylation of Protein Kinase B (PKB/Akt) and anti-apoptotic signalling but there is little known about the link between gastrins and PPARgamma receptors in relation to apoptosis.

Report this publication

Statistics

Seen <100 times